Hematopoietic stem cell transplantation in sickle cell patients
DOI:
https://doi.org/10.29327/2393773.16.1-13Keywords:
sickle cell anemia; hematopoietic stem cell transplantation; bone marrow transplant.Abstract
Aims: to carry out an integrative review on the use of HSCT in the DF. Method: integrative bibliographic review using the PUBMED database, and the following descriptors, hematopoietic stem cell transplantation and sickle cell disease. Results: HSCT is safe and effective for pediatric sickle cell patients who do not have an apparent HLA-identical donor and there is the possibility of performing haploidentical HSCT. In adult patients or patients with severe DF sequelae, reduced intensity conditions are being trained to improve the stages. Studies with mesenchymal cells have the potential to improve outcomes for patients undergoing HSCT. Conclusion: for the pediatric sickle cell population with severe symptoms, HSCT should be offered to improve quality of life, including with a haploidentical donor. For the adult population, individualized assessment will be necessary, taking into account the experience of the transplant team and the patient's clinical conditions.References
ALZAHRANI, M.; DAMIAJ, M.; JEFFRIES, N.; ALAHMARI, B.; SINGH, A.; RONDELLI, D.; et al. Non-myeloablative human leukocyte antigen-matched related donor transplantation in sickle cell disease: outcomes from three independent centres. British Journal of Haematology, v.192, n.4, p. 1-17, 2021. Acesso em 30 jan. 2024.
AYDIN, M.; DOVERN, E.; LEEFLANG, M.M.G.; DE LA FUENTE, J.; KASSIM, A.A.; BIEMOND, B.J.; NUR, E. Haploidentical Allogeneic Stem Cell Transplantation in Sickle Cell Disease: A Systematic Review and Meta-Analysis. Transplantation and Cellular Therapy, v.27, n.1, p. 1-8, 2021. Acesso em 01 fev. 2024.
BRANDOW, A. M.; LIEM, R. I. Advances in the diagnosis and treatment of sickle cell disease. Journal of Hematology & Oncology, v. 15, n. 1, p. 1-13, 2022. Acesso em: 09 fev. 2024
DE SANTIS, G.C.; COSTA, T.C.M.; SANTOS, F.L.S.; SILVA-PINTO, A.C.; STRACIERI, A.B.P.L.; PIERONI, F.; et al. Blood transfusion support for sickle cell patients during haematopoietic stem cell transplantation: a single-institution experience. British Journal of Haematology, v.190, n.1, p. 289-321, 2020. Acesso em 30 jan. 2024.
DOVERN, E.; NIJLAND, A.J.A.M.; MUILEKON, M.M.; SUIJK,L.M.J.; HOOGEDOON, G.M.; MEKELAKAMP, H.; et al. Physical, Mental, and Social Health of Adult Patients with Sickle Cell Disease after Allogeneic Hematopoietic Stem Cell Transplantation: A Mixed-Methods Study. Transplantation and Cellular Therapy, v.29, n.1, p. 1-9, 2023. Acesso em 01 fev. 2024.
EAPEN, M.; BRAZAUSKA R.; WALTERS M. C.; BERNAUDIN,F.; BO-SUBAIT, K. FITZHUGH, C.D.; et al. Effect of Donor Type and Conditioning Regimen Intensity on Allogeneic Transplantation Outcomes in Patients With Sickle Cell Disease: a Retrospective Cohort Study. Lancet Haematol., v. 6, n. 11, p. 1-22, 2019. Acesso em: 29 jan. 2024
ENGEL, E. R.; HOWARD, A. L.; ANKUS, E.J.; RICO, J . F. Advances in Sickle Cell Disease Management. Advances in Pediatrics, v. 67, p. 57–71, 2020. Acesso em: 30 jan. 2024.
FURSTENAU, D.; PEER, C.J.; HUGHES, T.E.; UCHIDA, N.; TISDALE, J.; HALL, O.M.; et al. Alemtuzumab clearance, lymphocyte count, and T-cell chimerism after hematopoietic stem cell transplant in sickle cell disease. Pharmacotherapy, v. 42, n.1, p. 1-17, 2022. Acesso em 30 jan. 2024.
IQBAL, M.; RELJIC, T.; CORBACIOGLU, S.; DE LA FUENTE, J.; GLUCKMAN, E.; KUMAR, A.; YASSINE, F.; et al. Systematic Review/Meta-Analysis on Efficacy of Allogeneic Hematopoietic Cell Transplantation in Sickle Cell Disease: An International Effort on Behalf of the Pediatric Diseases Working Party of European Society for Blood and Marrow Transplantation and the Sickle Cell Transplantation International Consortium. Transplantation and Cellular Therapy, v.27, n.1, p. 12-24, 2021. Acesso em 01 fev. 2024.
KRISHNMURTI, L.; NEUBERG, D.S.; SULLIVAN, K.M.; KAMANI, N.R.; ABRAHAM, A. CAMPIGOTTO, F.; et al. Bone Marrow Transplantation for Adolescents and Young Adults with Sickle Cell Disease: Results of a Prospective Multicenter Pilot Study. American Journaul of Hematology, v.94, n.4, p. 1-19, 2019. Acesso em 30 jan. 2024.
MAHESRI, M.; SCHNEEWEISS, S.; GLOBE, D.; LEVIN, R.; MCKERRACHER, K.; MUTEBI, A.; et al. Clinical Outcomes Following Bone Marrow Transplantation in Patients With Sickle Cell Disease: A Cohort Study of US Medicaid Enrollees. European Journal of Haematology, v. 106, n. 2, p. 273–280, 2021. Acesso em: 30 jan. 2024.
NICKEL, R.S.; HORAN, J.T.; ABRAHAM, A.; QAYED, M.; HAIGHT, A.; NGWUBE, A.; et al. Human leukocyte antigen (HLA) class I antibodies and transfusion support in paediatric HLA-matched haematopoietic cell transplant for sickle cell disease. British Journal of Haematology, v.189, n.1, p. 162-170, 2020. Acesso em 30 jan. 2024.
RIBEIRO, T.O.; SILVEIRA, B.M.; MEIRA, M.C.; CARREIRA, A.C.O.; SOGAYAR M.C.; MEYER, R.; FORTUNA, V. Investigating the potential of the secretome of mesenchymal stem cells derived from sickle cell disease patients. Plos One, v. 14, n. 10, p. 1-19, 2019. Acesso em 07 de mar. 2014.
SHAH , N.C.; BHOOPATIRAJU, S.; ABRAHAM, A.; ANDERSON, E.; ANDREANSKY, M.; BHATIA, M.; et al. Granulocyte Colony-Stimulating Factor Is Safe and Well Tolerated following Allogeneic Transplantation in Patients with Sickle Cell Disease. Transplantation and Cellular Therapy, v.28, n.1, p. 1-5, 2022. Acesso em 30 jan.. 2024.
STENGER, E.O.; CHINADDURAI, R., YUAN, S.; GARCIA, M.; ARAFAT, D.; GIBSON, G.; KRISHNAMURTI, L.; GALIPEAU, J. Bone Marrrow derived Mesenchymal Stromal cells from sickle cell disease patients display intact funcionality. Biol Blood Marrow Transplant, v. 23, n. 5, p. 1-21, 2017. Acesso em 07 de mar. 2024.
TANG, A.; STRAT, A.N.; RAHMAN, M.; ZANGH, H.; BAO, W.; LIU, Y.; SHI, D.; et al. Murine bone marrow mesenchymal stromal cells have reduced hematopoietic maintenance ability in sickle cell disease. Blood, v. 138, n. 24, p. 2570-252, 2021. Acesso em 07 de mar. 2024.
Downloads
Published
Issue
Section
License
Transferência de Direitos Autorais
Declaro que em caso de aceitação do artigo, concordo que os direitos autorais a ele referentes se tornarão propriedade exclusiva da Revista Interdisciplinar.
Assinatura do(s) autor(es)
Data: _____________________________________________________________________
Envio de manuscritos
Os manuscritos devem ser enviados pelo sistema eletrônico para a Revista Interdisciplinar.
